8 completed, 2 recruiting. 6 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Recruiting 2 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow TEZ: new trials by email Literature Review of TEZ trials Research Report on TEZ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants VX-272, Placebo, Tezacaftor - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 160 | 2026-02-25 | 2026-09-23 |
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis VX-828, Placebo, Itraconazole - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 165 | 2023-12-12 | 2026-08-10 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX-121, TEZ, VX-561 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 87 | 2019-04-30 | 2023-04-20 |
| A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis VX-659, TEZ/IVA, IVA - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 124 | 2017-08-08 | 2021-04-22 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis VX-659, Tezacaftor, Ivacaftor - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 163 | 2016-11-01 | 2017-09-05 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) TEZ, TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 83 | 2016-11-01 | 2020-03-04 |
| A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis TEZ, IVA, VX-440 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 74 | 2016-10-01 | 2020-08-28 |
| A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects VX-440, TEZ, IVA - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 16 | 2016-07-20 | 2018-04-03 |
Cystic Fibrosis (10)
Vertex Pharmaceuticals Incorporated (10)
United States (8) · United Kingdom (5) · Australia (2) · Belgium (2) · Canada (2) · Germany (2) · Netherlands (2) · Austria (1) · Denmark (1) · Ireland (1) · Israel (1) · Italy (1) · Portugal (1) · Spain (1)
PMID 33331662, PMID 37983082, PMID 30334693, PMID 30334692, PMID 31253540, PMID 36842446
2016 (4), 2017 (2)